SCHEMBL676563

SCHEMBL676563

CCCCCc1nc2[nH]c3ccc(C=Cc4ccccc4)cc3c2cc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.38
IP6K1 Q92551 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DHFR P00374 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
CNR2 P34972 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
PARP1 P09874 1/20 0.34
MCHR1 Q99705 2/20 0.34
ALK Q9UM73 2/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677054 0.89 GHSR (0.40) KDM4ECYP1A2CYP3A4SMN1; SMN2NPC1
SCHEMBL675099 0.85 TLR8 (0.45) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL677179 0.84 DHFR (0.42) KDM4ECYP1A2CYP3A4TSHRHSD17B10
SCHEMBL3725587 0.81 GABRP (0.40) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL3725585 0.81 GABRP (0.40) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL676276 0.80 MCHR1 (0.41) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL3728948 0.78 GABRP (0.39) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL3728950 0.78 GABRP (0.39) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL676306 0.75 MAPKAPK2 (0.38) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4
SCHEMBL676307 0.75 MAPKAPK2 (0.38) MAPKAPK2IP6K1KDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 MAPKAPK2 2823/4885IP6K1 3330/4885KDM4E 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.